Fluvoxamine for the treatment of COVID-19

doi:10.1016/S2214-109X(21)00592-1

Comment

. 2022 Mar;10(3):e331.

doi: 10.1016/S2214-109X(21)00592-1.

Fluvoxamine for the treatment of COVID-19

Catia Marzolini¹, Fiona Marra², Alison Boyle², Saye Khoo³, David J Back³

Affiliations

¹ Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: catia.marzolini@usb.ch.
² Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.
³ Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

PMID: 35180411
PMCID: PMC8846616
DOI: 10.1016/S2214-109X(21)00592-1

Comment

Fluvoxamine for the treatment of COVID-19

Catia Marzolini et al. Lancet Glob Health. 2022 Mar.

. 2022 Mar;10(3):e331.

doi: 10.1016/S2214-109X(21)00592-1.

Authors

Catia Marzolini¹, Fiona Marra², Alison Boyle², Saye Khoo³, David J Back³

Affiliations

¹ Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: catia.marzolini@usb.ch.
² Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Pharmacy, NHS Greater Glasgow and Clyde, Glasgow, UK.
³ Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

PMID: 35180411
PMCID: PMC8846616
DOI: 10.1016/S2214-109X(21)00592-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

CM received a research grant from Gilead; and lecture honoraria from Merck Sharpe and Dohme and ViiV Healthcare. FM has received an educational grant from Gilead Sciences and Abbvie; consultancy fees from Gilead Sciences, ViiV Healthcare, and Merck; and lecture fees from Gilead and ViiV. AB has received educational grants and lecture honoraria from Gilead and Abbvie. SK has received educational grants for the Liverpool drug interaction website (www.covid-druginteractions.org), AbbVie, Gilead Sciences, Merck Sharpe and Dohme, Novartis, and Sobi; speakers’ honoraria from ViiV Healthcare, Gilead Sciences, and AbbVie; consultancy fees from ViiV Healthcare and Merck; and research funding from Gilead Sciences, and ViiV Healthcare. DJB has received educational grants from AbbVie, Novartis, Merck, Gilead, and Sobi; DJB has received lecture fees from AbbVie, Gilead Sciences, Merck, ViiV Healthcare; and consultancy fees from Gilead Sciences.

Comment on

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ; TOGETHER investigators. Reis G, et al. Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28. Lancet Glob Health. 2022. PMID: 34717820 Free PMC article. Clinical Trial.
Fluvoxamine for the treatment of COVID-19.
Boulware DR, Abassi M. Boulware DR, et al. Lancet Glob Health. 2022 Mar;10(3):e329. doi: 10.1016/S2214-109X(21)00590-8. Lancet Glob Health. 2022. PMID: 35180409 Free PMC article. No abstract available.
Fluvoxamine for the treatment of COVID-19.
Kim H, Manzi S, Gonzelez-Heydrich J, Picker J. Kim H, et al. Lancet Glob Health. 2022 Mar;10(3):e330. doi: 10.1016/S2214-109X(22)00003-1. Lancet Glob Health. 2022. PMID: 35180410 Free PMC article. No abstract available.

Cited by

Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.
Lim SYM, Al Bishtawi B, Lim W. Lim SYM, et al. Eur J Drug Metab Pharmacokinet. 2023 May;48(3):221-240. doi: 10.1007/s13318-023-00826-8. Epub 2023 Apr 24. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37093458 Free PMC article. Review.
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19.
Asadi Anar M, Foroughi E, Sohrabi E, Peiravi S, Tavakoli Y, Kameli Khouzani M, Behshood P, Shamshiri M, Faridzadeh A, Keylani K, Langari SF, Ansari A, Khalaji A, Garousi S, Mottahedi M, Honari S, Deravi N. Asadi Anar M, et al. Front Pharmacol. 2022 Nov 30;13:1036093. doi: 10.3389/fphar.2022.1036093. eCollection 2022. Front Pharmacol. 2022. PMID: 36532776 Free PMC article. Review.
Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
Yu CL, Carvalho AF, Thompson T, Tsai TC, Tseng PT, Hsu CW, Tu YK, Yang SN, Hsu TW, Yeh TC, Liang CS. Yu CL, et al. Int J Environ Res Public Health. 2023 Feb 24;20(5):4088. doi: 10.3390/ijerph20054088. Int J Environ Res Public Health. 2023. PMID: 36901099 Free PMC article. Review.
Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine.
Marques L, Vale N. Marques L, et al. Pharmaceutics. 2023 May 24;15(6):1586. doi: 10.3390/pharmaceutics15061586. Pharmaceutics. 2023. PMID: 37376035 Free PMC article.
Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis.
Tsiakalos A, Ziakas PD, Polyzou E, Schinas G, Akinosoglou K. Tsiakalos A, et al. Microorganisms. 2023 Aug 12;11(8):2073. doi: 10.3390/microorganisms11082073. Microorganisms. 2023. PMID: 37630633 Free PMC article.

See all "Cited by" articles

References

1. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51. - PMC - PubMed
1. University of Liverpool COVID-19 Drug interaction. https://www.covid19-druginteractions.org
1. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29(suppl 1):1–9. - PubMed
1. Jazz Pharmaceuticals Fluvoxamine (Luvox highlights of prescribing information 2008) Nov 23, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022235lbl.pdf

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources

[1] Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51. - PMC - PubMed

[2] Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51. - PMC - PubMed

[3] University of Liverpool COVID-19 Drug interaction. https://www.covid19-druginteractions.org

[4] University of Liverpool COVID-19 Drug interaction. https://www.covid19-druginteractions.org

[5] Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29(suppl 1):1–9. - PubMed

[6] Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29(suppl 1):1–9. - PubMed

[7] Jazz Pharmaceuticals Fluvoxamine (Luvox highlights of prescribing information 2008) Nov 23, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022235lbl.pdf

[8] Jazz Pharmaceuticals Fluvoxamine (Luvox highlights of prescribing information 2008) Nov 23, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022235lbl.pdf

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Fluvoxamine for the treatment of COVID-19

Affiliations

Fluvoxamine for the treatment of COVID-19

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources